Pneumonia Clinical Trial
Official title:
A Randomized, Double-blind, Parallel-Controlled Phase III Clinical Trial of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants
NCT number | NCT02494999 |
Other study ID # | JSVCT022 |
Secondary ID | |
Status | Completed |
Phase | Phase 3 |
First received | |
Last updated | |
Start date | June 2016 |
Est. completion date | October 2019 |
Verified date | May 2020 |
Source | Jiangsu Province Centers for Disease Control and Prevention |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
In order to evaluate immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine produced by Beijing Minhai Biotechnology Co., Ltd., a randomized, double-blind, parallel-controlled phase III clinical trial is planned to conduct in healthy infants aged 2 months in China.
Status | Completed |
Enrollment | 1200 |
Est. completion date | October 2019 |
Est. primary completion date | December 2018 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 42 Days to 77 Days |
Eligibility |
Inclusion Criteria: - Aged 42-77 days old on the day of inclusion - Subjects' legal guardians are able to understand and sign the informed consent - Subjects' legal guardians can and will comply with the requirements of the protocol - Subjects with temperature <=37.0°C on axillary setting Exclusion Criteria for First Vaccination: - Preterm infants or low birth weight infants - Any administration history of pneumococcal polysaccharide vaccine or pneumococcal conjugate vaccine - A medical history of culture-confirmed invasive disease caused by Streptococcus pneumonia - Subject who has allergic history or serious adverse reaction history after vaccination such as allergies, hives, difficulty in breathing, angioedema or abdominal pain - Subject with congenital malformation, developmental disorder, genetic defects or severe malnutrition - Subject with epilepsy, a history of seizures or convulsions, or a family history of mental illness - Known or suspected immune deficiency or immune suppression - Diagnosed coagulation abnormalities (such as clotting factor deficiency, coagulation disorders, platelet disorder) or significant bruising or blood clotting disorder - Had immunosuppressive therapy, cytotoxic therapy, inhaled corticosteroids (not including allergic rhinitis corticosteroid spray treatment, acute uncomplicated dermatitis surfaces corticosteroid therapy) in the past 6 months - Any prior administration of blood products in last 3 months - Any prior administration of any attenuated live vaccine in last 14 days - Any prior administration of subunit or inactivated vaccines in last 7 days - Any acute infection or serious infection needing systemic antibiotics or antiviral treatment in last 7 days - Any fever with temperature >=38.0°C on axillary setting in last 3 days - Any other factors judged by investigator, that may interfere subject's compliance with the protocol Exclusion Criteria for Second/Third and Booster Vaccination: If one of the following (1) to (3) adverse events (AE) occurs, further vaccination is prohibited, but other study steps can be continued according to the judgment of the investigators; If one of the following (4) to (5) adverse events occurs, the investigator shall determine whether to continue the following vaccination. In the event of one of the following adverse events (6) to (7), vaccination may be postponed within the time window specified in the protocol. - (1)The subjects have suffered from severe adverse events caused by the previous vaccination. - (2)The subjects suffered from severe allergic reactions or hypersensitivity after the previous vaccination. - (3)Known or suspected autoimmune diseases or immunodeficiency diseases,including HIV infection. - (4)The occurrence of acute or emerging chronic diseases at the time of vaccination. - (5)Other reactions (including severe pain, severe swelling, severe restriction of movement, persistent high fever, severe headache, or other systemic or local reactions) judged by the investigators. - (6)Acute illness (acute illness refers to moderate or severe illness with or without fever) at the time of vaccination. - (7)The axillary temperature >37.0? at the time of vaccination. |
Country | Name | City | State |
---|---|---|---|
China | Hongze District Center for Disease Control and Prevention | Huai'an | Jiangsu |
China | Huaiyin District Center for Diseases Control and Prevention | Huai'an | Jiangsu |
China | Lianshui County Center for Disease Control and Prevention | Huai'an | Jiangsu |
China | Guanyun County Center for Disease Control and Prevention | Lianyungang | Jiangsu |
Lead Sponsor | Collaborator |
---|---|
Jiangsu Province Centers for Disease Control and Prevention | Beijing Minhai Biotechnology Co., Ltd |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Proportion of subjects with serotype-specific pneumococcal IgG antibody concentration = 0.35 ug/mL 30 days after primary vaccination | Proportion of subjects with serotype-specific pneumococcal IgG antibody concentration = 0.35 ug/mL 30 days after primary vaccination | 30 days after primary vaccination | |
Primary | Geometric mean concentration (GMC) of serotype-specific pneumococcal IgG antibody 30 days after primary vaccination | Geometric mean concentration (GMC) of serotype-specific pneumococcal IgG antibody 30 days after primary vaccination | 30 days after primary vaccination | |
Secondary | Proportion of subjects with serotype-specific pneumococcal IgG antibody concentration = 1.0 ug/mL 30 days after primary vaccination | Proportion of subjects with serotype-specific pneumococcal IgG antibody concentration = 1.0 ug/mL 30 days after primary vaccination | 30 days after primary vaccination | |
Secondary | Geometric mean fold increase (GMI) of serotype-specific pneumococcal IgG antibody 30 days after primary vaccination | Geometric mean fold increase (GMI) of serotype-specific pneumococcal IgG antibody 30 days after primary vaccination | 30 days after primary vaccination | |
Secondary | Proportion of subjects with serotype-specific geometric mean titer measured by OPA =1:8 30 days after primary vaccination | Proportion of subjects with serotype-specific geometric mean titer measured by OPA =1:8 30 days after primary vaccination | 30 days after primary vaccination | |
Secondary | Geometric mean titer (GMT) of serotype-specific pneumococcal IgG antibody measured by OPA 30 days after primary vaccination | Geometric mean titer (GMT) of serotype-specific pneumococcal IgG antibody measured by OPA 30 days after primary vaccination | 30 days after primary vaccination | |
Secondary | Proportion of subjects with serotype-specific pneumococcal IgG antibody concentration = 0.35 ug/mL 30 days after booster vaccination | Proportion of subjects with serotype-specific pneumococcal IgG antibody concentration = 0.35 ug/mL 30 days after booster vaccination | 30 days after booster vaccination | |
Secondary | Proportion of subjects with serotype-specific pneumococcal IgG antibody concentration = 1.0 ug/mL 30 days after booster vaccination | Proportion of subjects with serotype-specific pneumococcal IgG antibody concentration = 1.0 ug/mL 30 days after booster vaccination | 30 days after booster vaccination | |
Secondary | Geometric mean concentration (GMC) of serotype-specific pneumococcal IgG antibody 30 days after booster vaccination | Geometric mean concentration (GMC) of serotype-specific pneumococcal IgG antibody 30 days after booster vaccination | 30 days after booster vaccination | |
Secondary | Proportion of subjects with serotype-specific geometric mean titer measured by OPA =1:8 30 days after booster vaccination | Proportion of subjects with serotype-specific geometric mean titer measured by OPA =1:8 30 days after booster vaccination | 30 days after booster vaccination | |
Secondary | Geometric mean titer (GMT) of serotype-specific pneumococcal IgG antibody measured by OPA 30 days after booster vaccination | Geometric mean titer (GMT) of serotype-specific pneumococcal IgG antibody measured by OPA 30 days after booster vaccination | 30 days after booster vaccination | |
Secondary | Incidence of adverse reactions (including systemic and local adverse reaction) 30 days after each dose of vaccination | Incidence of adverse reactions (including systemic and local adverse reaction) 30 days after each dose of vaccination | 30 days after each dose of vaccination | |
Secondary | Incidence of severe adverse event (SAE) within 6 months after the first doseof vaccination | Incidence of severe adverse event (SAE) within 6 months after the first doseof vaccination | 6 months after the first doseof vaccination | |
Secondary | Incidence of severe adverse event (SAE) 30 days after booster vaccination | Incidence of severe adverse event (SAE) 30 days after booster vaccination | 30 days after booster vaccination |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04244474 -
Effect of Vitamin D Supplementation on Improvement of Pneumonic Children
|
Phase 1/Phase 2 | |
Completed |
NCT05815264 -
Clinical Trial of 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Chinese Population Aged 2 Years and Above
|
Phase 1 | |
Recruiting |
NCT04589936 -
Prone Position to Improve Oxygenation in COVID-19 Patients Outside Critical Care
|
N/A | |
Completed |
NCT02905383 -
The Effect of Exercise on Physical Function and Health in Older People After Discharge From Hospital
|
N/A | |
Terminated |
NCT03944551 -
Bubble Continuous Positive Airway Pressure for Children With Severe Pneumonia in Mali, Africa
|
N/A | |
Completed |
NCT06210737 -
A Study to Evaluate Persistence of Immunity of PCV13 in Healthy Population Aged 2 Months,7 Months-5 Years
|
Phase 4 | |
Terminated |
NCT04660084 -
Impact of Molecular Testing on Improved Diagnosis, Treatment and Management of CAP
|
N/A | |
Not yet recruiting |
NCT05649891 -
Checklists Resuscitation Emergency Department
|
N/A | |
Withdrawn |
NCT05702788 -
Efficacy and Safety of Jaktinib in Participants With Severe Novel Coronavirus Pneumonia(COVID-19)
|
Phase 2 | |
Not yet recruiting |
NCT04171674 -
Pharmacokinetics of High-dose Ceftobiprole in Community-acquired Pneumonia Under Mechanical Ventilation.
|
N/A | |
Active, not recruiting |
NCT03140163 -
Screening for Pneumonia: A Comparison of Ultra Low Dose Chest CT [ULD-CT] and Conventional Chest Radiography [CXR]
|
N/A | |
Completed |
NCT02638649 -
Prehospital Use of Ultrasound in Undifferentiated Shortness of Breath
|
||
Completed |
NCT02864420 -
Hospitalization at Home: The Acute Care Home Hospital Program for Adults
|
N/A | |
Recruiting |
NCT02515565 -
Physiotherapy in Patients Hospitalized Due to Pneumonia.
|
N/A | |
Completed |
NCT02105298 -
Effect of Volume and Type of Fluid on Postoperative Incidence of Respiratory Complications and Outcome (CRC-Study)
|
N/A | |
Completed |
NCT01416519 -
Physiotherapy Technique Decreases Respiratory Complications After Cardiac Operation
|
N/A | |
Completed |
NCT01446926 -
Study of Investigational Pneumococcal Vaccine in Healthy Adults, Toddlers and Infants
|
Phase 1 | |
Completed |
NCT01399723 -
Amoxicillin Versus Benzyl Penicillin for Treatment of Children Hospitalised With Severe Pneumonia
|
Phase 3 | |
Completed |
NCT01416506 -
Community-Acquired Pneumonia (CAP) Surveillance
|
N/A | |
Terminated |
NCT02358642 -
Drug to Prevent Pneumonia in the Tube Fed
|
Phase 4 |